Comparison · NCT03106779-0d1a25f5
Asciminib vs Bosutinib: Number of Participants With Major Molecular Response (MMR) Rate at 24 Weeks
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Asciminib vs Bosutinib: Number of Participants With Major Molecular Response (MMR) Rate at 24 Weeks. Trial comparisons, record NCT03106779-0d1a25f5. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03106779-0d1a25f5
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.255 | 0.193 | 0.328 | wilson | |
| Risk in group 2 | 0.132 | 0.0731 | 0.226 | wilson | |
| Risk difference, group 1 minus group 2 | 0.123 | 0.0108 | 0.217 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.94 | 1.02 | 3.66 | log | |
| Odds ratio, group 1 over group 2 | 2.26 | 1.06 | 4.8 | log | |
| Number needed to treat, for one more participant with the outcome on Asciminib than on Bosutinib | 8.12 | 4.61 | 92.9 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Asciminib | Patients randomized to asciminib 40mg BID | 40 | 157 | OG000 |
| Group 2 | Bosutinib | Patients randomized to bosutinib 500mg QD | 10 | 76 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Major Molecular Response (MMR) Rate at 24 Weeks
- Description
- MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by IS as measured by RQ-PCR.
- Time frame
- 24 weeks
- Population
- Full Analysis Set (FAS): The FAS comprised of all randomized patients.
Source ClinicalTrials.gov
Trial
- Title
- Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
- NCT number
- NCT03106779
- Phases
- PHASE3
- Conditions
- Chronic Myelogenous Leukemia
- Interventions
- Asciminib, Bosutinib
- Lead sponsor
- Novartis Pharmaceuticals
- Results first posted
- 2022-02-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03106779?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03106779-0d1a25f5